ICCM News and Press, IceCure Medical Ltd. From 10/26/22

IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month PR Newswire ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back...

The shares of Israeli medical device maker IceCure Medical Ltd ( NASDAQ: ICCM ) added ~19% pre-market Wednesday after the company announced it submitted a regulatory filing to obtain FDA clearance for ProSense System to treat breast cancer. ProSense System is designed ...

IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery PR Newswire 43,000 cases estimated annually in the U.S. alone f...

IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil PR Newswire Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil ProSense Cryoablation System approval in Brazil is pending ...

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense® PR Newswire Company is rapidly expanding its global regulatory and commercial reach CAESAREA, Israel , Aug. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICC...

IceCure Medical Ltd (ICCM) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Eyal Shamir – Chief Executive Officer Ronen Tsimerman – Chief Financial Officer Kenneth Tomkovich – Co-Primary Investigator Conf...

IceCure Medical press release ( NASDAQ: ICCM ): 1H GAAP EPS of -$0.24 (vs. -$0.16 Y/Y). Revenue of $1.5M (-28.6% Y/Y) beats by $0.75M . For further details see: IceCure Medical 1H GAAP EPS of -$0.24, revenue of $1.5M beats by $0.75M

IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights PR Newswire Conference call scheduled for 4:30 p.m. EDT today Exclusive distribution agreement signed with Shanghai Medtronic Zhikang Medical Devi...

IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022 PR Newswire CAESAREA, Israel , Aug. 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-inva...

IceCure Medical ( NASDAQ: ICCM ) said on Monday it had submitted regulatory filing with the Canadian governmental agency for approval of its cancer killing device, ProSense System and its cryoprobes, to treat a number of cancers, including breast cancer, lung cancer, renal...